Abstract
As the COVID-19 pandemic continues with ongoing variant waves and vaccination efforts, population-level immunity and public risk perceptions have shifted. This study presents a behavioral transmission model to assess how virus spread and care-seeking behavior differ based on individuals' immunity status. We categorized the population into two groups: "partially immune" and "susceptible" which influenced their response to vaccination and testing, as well as their prioritization of information related to disease prevalence and severity. Using COVID-19 data from South Korea (February 1, 2022 - May 31, 2022), we calibrated our model to explore these dynamics. Simulation results suggest that increasing reactivity to information among partially immune individuals to the same level as susceptible individuals could reduce peak active cases by 16%. Conversely, if partially immune individuals shift their risk perception focus from prevalence (90% prevalence vs. 10% severity) to severity (90% severity vs. 10% prevalence), the peak in active cases could increase by 50%. These findings highlight the need for adaptive vaccination and testing strategies as public risk perceptions evolve due to prior exposures and vaccinations. As new variant waves emerge in the post-pandemic endemic era, our study offers insights into how immunity-based behavioral differences can shape future infection peaks.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Grant of the project for Infectious Disease Medical Safety, funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HG22C0094)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at URL: https://datadryad.org/stash/share/_vm4gFgQ9uxMAFnSbGYLsD41b9l5anwnPKsO6W0YhpU
https://datadryad.org/stash/share/_vm4gFgQ9uxMAFnSbGYLsD41b9l5anwnPKsO6W0YhpU